Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Depreciation: 2017-2024

Historic Accumulated Depreciation for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $4.8 million.

  • Aclaris Therapeutics' Accumulated Depreciation rose 6.50% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 6.50%. This contributed to the annual value of $4.8 million for FY2024, which is 15.45% up from last year.
  • Aclaris Therapeutics' Accumulated Depreciation amounted to $4.8 million in FY2024, which was up 15.45% from $4.2 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Accumulated Depreciation ranged from a high of $4.8 million in FY2024 and a low of $2.6 million during FY2020.
  • In the last 3 years, Aclaris Therapeutics' Accumulated Depreciation had a median value of $4.2 million in 2023 and averaged $4.3 million.
  • Data for Aclaris Therapeutics' Accumulated Depreciation shows a peak YoY increased of 29.36% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Accumulated Depreciation stood at $2.6 million in 2020, then climbed by 29.36% to $3.4 million in 2021, then grew by 18.92% to $4.0 million in 2022, then climbed by 3.15% to $4.2 million in 2023, then increased by 15.45% to $4.8 million in 2024.